July 2, 2018 10:04am
Stock opened at $13.12 had jumped $2.19 or +19.54% to $13.60 having seen a high of $14.50
Preliminary revenue of $5.2 Million, up 103% Year-over-Year and 36% sequentially
… Represents a 103% increase from Q2/17 and a 36% increase from Q1/18
Management estimates that BLFS' proprietary bio-preservation media products have been used in nearly 300 customer clinical applications, including dozens of CAR T-cell and other T cell immunotherapies targeting blood cancers and solid tumors as well as other cell types targeting debilitating diseases and disorders.
Roderick de Greef, Chief Financial Officer, remarked, "Based primarily on additional warrant exercises during the period, we ended the second quarter with more than $14 million in cash, up from $7 million at March 31, 2018."
Management is raising its revenue guidance for the full year 2018:
- Bio-preservation media revenue is now expected to be in a range of $18.5 million to $20 million, representing growth of approximately 68% to 82% over 2017. This is an increase from BLFS’ prior revenue guidance issued in April 2018 of a range of $14.5 million to $15.5 million.
Management is affirming the remainder of its financial guidance for 2018 as follows:
- Gross margin is expected to be between 63% and 65%, up from 61% for 2017.
- Operating expenses are expected to range from $9.0 million to $9.5 million, compared with $7.8 million for 2017.
- Full year GAAP operating profit with proportional increases in adjusted EBITDA and cash flow from operations
One issue after a blow-out Q … What is going to KEEP investors IN the STOCK (?) as profiteering will sooner not later emasculate the shares!
ANY ... follow-on NEWS will be the KEY to pricing SUSTAINABILITY otherwise a FLASH in the pan in a short-term focused sector!